Characteristics | FLT3-ITD +  NPM1 + Fusion − | FLT3-ITD +  Fusion + NPM1 − | P valuea |
---|---|---|---|
n | 31 | 24 | Â |
Age, years Median(range) | 52 (14–76) | 36 (12–65) | 0.007 |
Male n (%) | 12 (38.7) | 11 (45.8) | 0.254 |
WBC at diagnosis, × 109/L Median(range) | 31.4 (1.3–405.1) | 10.8 (0.7–306.9) | 0.278 |
Blast in BM, % Median(range) | 68.8 (21.2–96.4) | 56.4 (11.2–95.6) | 0.543 |
FAB subtype | Â | Â | 0.671 |
 M0 | 0 (0) | 0 (0) |  |
 M1 | 1 (3.3) | 1 (4.2) |  |
 M2 | 8 (26.7) | 8 (33.3) |  |
 M4 | 13 (43.3) | 9 (37.5) |  |
 M5 | 6 (20.0) | 5 (20.8) |  |
 M6 | 0 (0) | 1 (4.2) |  |
 Unclassified | 0 (0) | 0 (0) |  |
 Secondary-AML | 2 (6.7) | 0 (0) |  |
Karyotype | Â | Â | 0.015 |
Favorable | 0 (0) | 7 (29.2) | Â |
Intermediate | 27 (87.1) | 13 (54.2) | Â |
 Normal | 22 (71) | 9 (37.5) | 0.007 |
 Others | 5 (16.1) | 4 (16.7) |  |
Unfavorable | 2 (6.5) | 3 (12.5) | Â |
Failed | 2 (6.5) | 1 (4.2) | Â |
Immunophenotype | Â | Â | Â |
 CD34 +  | 18/25 (72.0) | 20/22 (90.9) | 0.203 |
 CD13 +  | 25/26 (96.3) | 18/20 (90.0) | 0.814 |
 CD33 +  | 26/26 (100) | 21/22 (95.5) | 0.458 |
 CD117 +  | 23/25 (92) | 21/22 (95.5) | 1.000 |
 CD64 +  | 10/24 (41.7) | 5/11 (45.5) | 1.000 |
Mutations | Â | Â | Â |
 Average num | 3.6 | 2.2 | 0.000 |
 DNMT3A | 13/28 (46.4) | 2/22 (9.1) | 0.004 |
 Methylation-related genesb | 16/28 (57.1) | 4/22 (18.2) | 0.005 |
CR, n (%) | Â | Â | Â |
 Yes | 14/25 (56) | 17/24 (70.8) | 0.282 |
Relapse in 1Â year | Â | Â | Â |
 Yes | 16/22 (72.7) | 17/20 (85) | 0.460 |